Mineralocorticoid receptor overactivation: novel approach to treatment of multi-organ impact with finerenone
In this medfyle
The mineralocorticoid receptor is overactivated in CV risk, CKD, and T2D. Results trailing finerenone, a selective nonsteroidal mineralocorticoid receptor agonist, improved patient cardiorenal outcomes, irrespective of baseline anti-diabetic treatments.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Per-Henrik Groop
University of Helsinki
Helsinki, Finland
Dr. Maria Luiza Caramori
University of Minnesota
Minneapolis, MN, USA
Dr. Janet B. McGill
Washington University
St. Louis, MO, USA
Dr. Peter Rossing
Steno Diabetes Center
Copenhagen, Denmark
Prof. Andreas L. Birkenfeld
Medizinische Universitätsklinik
Tübingen, Germany
Dr. Jennifer Green
Duke Clinical Research Institute
Durham, NC, USA
Dr. Hiddo Lambers Heerspink
University Medical Center Groningen
Groningen, Netherlands
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
